https://www.selleckchem.com/pr....oducts/incb28060.htm
Carboplatin hypersensitivity reactions have been reported to occur in up to 16% of patients with gynecologic cancers. Several predisposing factors have been suggested including presence of BRCA1/2 mutation, however, contribution of these mutations to reaction development has not been extensively studied. The purpose of this study was to determine if there is an association between BRCA1/2 mutation status and the development of carboplatin hypersensitivity reactions. Eligible patients were women aged 18 years or older with a diagnosis
Gefällt mir
Kommentar
Teilen
